James Link, PhD
Hematology & Oncology · Lone Tree, CONPI 1063775104
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 9.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,602 and has fallen 99.0% since, to $15 in 2024.
Across 282 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$426
- Johnson & Johnson$401
- Astellas Pharma US Inc$323
- Seagen Inc.$270
- Sanofi$251
- Novartis$241
- plus $3K from 35 others
What the payments were for
- Food & beverage$4,36494%
- Education$2586%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 38 | $426 |
| Johnson & Johnson | 34 | $401 |
| Astellas Pharma US Inc | 24 | $323 |
| Seagen Inc. | 16 | $270 |
| Sanofi | 12 | $251 |
| Novartis | 15 | $241 |
| Genentech USA, Inc. | 17 | $238 |
| Merck | 11 | $188 |
| Sanofi-aventis U.S. LLC | 2 | $159 |
| Incyte Corporation | 9 | $155 |
| Eisai Inc. | 9 | $154 |
| Pfizer | 11 | $153 |
| GSK | 6 | $145 |
| Exelixis Inc. | 8 | $145 |
| Puma Biotechnology, Inc. | 7 | $139 |
| Daiichi Sankyo Inc. | 6 | $134 |
| Amgen | 6 | $116 |
| Gilead | 4 | $108 |
| Bristol Myers Squibb | 4 | $80 |
| Dendreon Pharmaceuticals LLC | 3 | $73 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $72 |
| AstraZeneca | 4 | $69 |
| AMAG Pharmaceuticals, Inc. | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Bayer | 3 | $53 |
| Tesaro, Inc. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Tolmar Pharmaceuticals, Inc. | 2 | $39 |
| AbbVie | 2 | $34 |
| Lilly USA, LLC | 2 | $32 |
| Boehringer Ingelheim | 2 | $32 |
| Mylan Institutional Inc. | 2 | $31 |
| Blueprint Medicines Corporation | 2 | $31 |
| Dova Pharmaceuticals | 1 | $19 |
| Morphosys, US Inc. | 1 | $18 |
| Beigene USA, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $10 |
How this compares
$4,622 in reported general payments places this provider in the 60th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 20 | $321,812 |
| CabometyxCabozantinib S-Malate | 12 | $260,484 |
| XareltoRivaroxaban | 30 | $24,607 |
| EliquisApixaban | 16 | $19,824 |
| NivestymFilgrastim-Aafi | 21 | $15,298 |
| Abiraterone Acetate | 92 | $13,548 |
| GranixTbo-Filgrastim | 25 | $10,290 |
| Prednisone | 153 | $1,153 |
| Prochlorperazine Maleate | 46 | $989 |
| Dexamethasone | 52 | $763 |
| Anastrozole | 32 | $707 |
| Tamoxifen Citrate | 30 | $700 |
| Hydroxyurea | 21 | $688 |
| Potassium Chloride | 49 | $564 |
| Ondansetron OdtOndansetron | 37 | $526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $32 | $321,81220 claims |
| Exelixis Inc.Cabometyx | $145 | $260,48412 claims |
| PfizerEliquis, Nivestym | $153 | $35,12137 claims |
| Johnson & JohnsonXarelto | $401 | $24,60730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Lone Tree
- Robert JotteLone Tree$80K
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.